Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Arrowhead Pharmaceuticals reports strong Q1 earnings and outlines growth strategy

Arrowhead Pharmaceuticals showcased solid financial performance, promising clinical outcomes, and a strategic growth plan during the Q1 2023 earnings call.
While facing challenges in financial losses and program complexities, the company's strengths in innovation, partnerships, and pipeline development position them for future success.
Opportunities lie in upcoming data releases, therapeutic advancements, and strategic collaborations, offering avenues for market expansion and medical breakthroughs.
Overall, Arrowhead Pharmaceuticals demonstrates resilience, innovation, and a clear vision for growth in the competitive biopharmaceutical landscape.

Arrowhead Pharmaceuticals reports robust Q2 earnings and expands pipeline

Arrowhead Pharmaceuticals delivered strong financial results and showcased progress in its drug pipeline, particularly in the pulmonary and CNS spaces.
While facing challenges in translating preclinical success to clinical outcomes and navigating competitive landscapes, the company's strategic partnerships and efficient cost management are key strengths.
Opportunities lie in expanding into new therapeutic areas, leveraging external interest for internal development, and benefiting from regulatory insights in the CNS field.
Overall, Arrowhead Pharmaceuticals remains well-positioned for future growth and innovation in the biopharmaceutical sector.

Arrowhead Pharmaceuticals advances pipeline with strong financial backing

Arrowhead Pharmaceuticals made progress in de-risking its pulmonary franchise and advancing key cardiometabolic candidates.
The company's strong financial position and focus on partnerships support its goal of expanding the pipeline to 20 products by 2025.
Challenges include high operating expenses, the need for specific financing for trials, and managing cash burn effectively.
Exploration of CNS targets and upcoming Phase 2 data presentations offer growth opportunities for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals advances key products towards commercialization amid financial challenges

Arrowhead Pharmaceuticals made significant progress on key products and is advancing towards commercialization and de-risking their pipeline.
Despite facing a net loss, the company remains focused on expanding their product portfolio and exploring new treatment options.
Strategic partnerships and ongoing research efforts position Arrowhead well for future growth and potential commercial success.
Managing financial challenges and optimizing trial strategies will be crucial for Arrowhead's continued success in the biopharmaceutical industry.

Arrowhead Pharmaceuticals advances RNAi pipeline with cardiometabolic focus

Arrowhead Pharmaceuticals focuses on advancing RNAi therapeutics with a cardiometabolic emphasis.
Financials show a net loss with plans to strengthen the balance sheet and decrease operating expenses.
Exploring debt financing, partnerships, and new innovations for pipeline expansion and commercial growth.
Challenges include data delays, uncertain timelines, and the need for additional biomarker data.

Arrowhead Pharmaceuticals reports strong fiscal 2024 results and strategic partnerships

Arrowhead Pharmaceuticals' fiscal 2024 performance was robust, fueled by a game-changing partnership with Sarepta and promising results in the cardiometabolic pipeline.
While facing challenges in differentiation and portfolio management, the company's proactive approach and strong financial position present opportunities for growth and innovation.
Strategic collaborations, ongoing Phase III studies, and plans for debt repayment through partnership cash flows underscore Arrowhead's commitment to value creation and sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has voluntarily paused the AROENaC1001 Phase 1/2 study evaluating ARO-ENaC for cystic fibrosis. ARO-ENaC is the company's investigational RNA interference (RNAi) therapeutic.

Arrowhead Stock Drops After RNAi Therapeutic Shows Lung Inflammation In Animal Models

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study

Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals dosed the first patient in a Phase 2b clinical study of ARO-ANG3 an RNAi therapeutic to treat mixed dyslipidemia

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead and Takeda presented positive clinical trial data on rare orphan disease RNAi drug ARO-AAT at EASL The International Liver Congress

Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals presented preclinical data on the development of ARO-DUX4 at 28th Annual FSHD Society International Research Congress

Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead presents data at EASL showing ARO-HSD reduces HSD17B13 mRNA and protein in the liver leading to reductions in ALT

Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress

Horizon Pharma

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) have entered into a global collaboration and license agreement for ARO-XDH for uncontrolled gout. Horizon will pay $40 million upfront for global rights to Arrowhead Pharmaceuticals' ARO-XDH, an investigational RNAi therapy.

Horizon Acquires Rights to Arrowhead's RNAi-Based Gout Treatment Candidate

PASADENA, Calif. & DUBLIN--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) today announced a global collaboration and license agreement for ARO-XDH, a previously undisclosed discovery-stage investigational RNA interference (RNAi) therapeutic being developed by Arrowhead as a potential treatment for people with uncontrolled gout. Gout is a serious and painful form of arthritis that is caused by excess uric acid in the blood. In the Unite

Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout

As it harnesses the powerful RNAi platform coined TRiM, Arrowhead is brewing a robust pipeline of stellar medicines. ARO-AAT is poised to deliver robust clinical outcomes to give the stock more upsides.

Arrowhead: On Target With RNAi Innovation

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals dosed the first patient in a Phase 2b clinical study of ARO-APOC3 in patients with severe hypertriglyceridemia

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia

Johnson & Johnson

Janssen Pharmaceuticals Inc, part of Johnson & Johnson (NYSE: JNJ), has delivered written notice of its intent to exercise its option right for ARO-JNJ1. Receipt of the option notice earns Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) a $10 million option exercise fee.

Arrowhead Receives $10M Option Exercise Fee From Janssen

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals earns a $10 million option exercise fee from Janssen, part of Johnson & Johnson.

Arrowhead Earns $10 Million Option Exercise Fee

Arrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Q2 2021 Results - Earnings Call Transcript

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals today announced financial results for its fiscal second quarter ended March 31, 2021.

Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results

Arrowhead Pharmaceuticals is an inherently innovative biotech. Investigative drug research includes multiple trial phases, requiring great effort, time and significant cash.

Arrowhead Pharmaceuticals: Partnerships Boost A Bull Case

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced positive interim 48-week liver biopsy results from the Phase 2 AROAAT2002 study evaluating ARO-AAT for rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD). AATD is the lack of a protein made by the liver released into the bloodstream.

Arrowhead's ARO-AAT Treatment Associated With Improved Fibrosis In Patients With Alpha-1 Liver Disease

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Announces Improvement in Fibrosis after ARO-AAT, being co-developed with Takeda, in Patients with the rare genetic Alpha-1 Liver Disease

Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $ARWR--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced ARO-DUX4 as Arrowhead's first muscle targeted investigational RNAi therapeutic candidate to utilize its proprietary Targeted RNAi Molecule (TRIMTM) platform. ARO-DUX4 is designed to target the gene that encodes human double homeobox 4 (DUX4) protein as a potential treatment for patients with facioscapulohumeral muscular dystrophy (FSHD). Pending abstract acceptance, Arrowhead intends to present pre

Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform

Arrowhead Pharmaceuticals: RNAi And The Knockdown Effect

ARWR is progressing well with its A1AD lead indication. Normally, approval would be in 2023, but accelerated approval is not impossible.

Arrowhead: Steady Progress With Lead Indication, Vast Pipeline

In Q4 2020, we discussed why Arrowhead stock, a biopharmaceutical company that develops RNA interference therapies, looks attractive despite a stellar 16x move since early 2018. The stock has had a volatile ride since then.

Arrowhead Stock Looks Oversold At $65

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead submitted an IND to the U.S. Food and Drug Administration for ARO-APOC3, an RNAi therapeutic for hypertriglyceridemia

Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia

Biogen

Fortinet

Kohl's

Pinterest

Deckers Outdoor

Infinity Pharma

International Paper

Jazz Pharmaceuticals

Snap

With the trading day about halfway over, the broad markets were trading sideways into the weekend.

Biogen, Fortinet, Kohl's, Pinterest, Snap and More Friday Afternoon Analyst Calls

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q1 2021 Results - Earnings Call Transcript

News for Arrowhead Pharmaceuticals Stock (ARWR)